Markets:

Overview

News

Currencies

International

Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

75.76 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Earnings Scheduled For October 27, 2022 ↗

October 27, 2022

Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.

Via Benzinga

Reaction Is Overdone For PTC Therapeutics Pausing Huntington Trial Enrollment, Analyst Says ↗

October 19, 2022

Via Benzinga

PTC Therapeutics Pauses Enrollment In Huntington's Candidate Trial In US ↗

October 19, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 19, 2022

Gainers Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 74.8% to $0.17 during Wednesday's pre-market session. The company's market cap stands at $14.1 million.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 18, 2022

Gainers

Via Benzinga

Marten Transport, Silvergate Capital And Some Other Big Stocks Moving Lower On Tuesday ↗

October 18, 2022

U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

What 5 Analyst Ratings Have To Say About PTC Therapeutics ↗

October 17, 2022

Within the last quarter, PTC Therapeutics (NASDAQ:PTCT) has observed the following analyst ratings:

Via Benzinga

Expert Ratings for PTC Therapeutics ↗

October 17, 2022

Analysts have provided the following ratings for PTC Therapeutics (NASDAQ:PTCT) within the last quarter:

Via Benzinga

Analyst Ratings for PTC Therapeutics ↗

October 17, 2022

Within the last quarter, PTC Therapeutics (NASDAQ:PTCT) has observed the following analyst ratings:

Via Benzinga

Analyst Ratings for PTC Therapeutics ↗

September 09, 2022

Analysts have provided the following ratings for PTC Therapeutics (NASDAQ:PTCT) within the last quarter:

Via Benzinga

PTC Therapeutics: Q2 Earnings Insights ↗

August 04, 2022

PTC Therapeutics (NASDAQ:PTCT) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Via Benzinga

Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients ↗

October 12, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2022 ↗

September 12, 2022

Upgrades

Via Benzinga

Newman Ferrara LLP Announces Corporate Governance Investigations of PTC Therapeutics (PTCT)

September 07, 2022

From Newman Ferrara LLP

Via Business Wire

Raymond James Says PTC Therapeutics' CHMP Backing Is 'Under Exceptional Circumstances' What's Next ↗

May 24, 2022

Via Benzinga

Europe's CHMP Backs Approval Of PTC Therapeutics' Gene Therapy In Rare Neurometabolic Disorder ↗

May 20, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗

September 09, 2022

Upgrades

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022 ↗

September 01, 2022

Upgrades

Via Benzinga

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗

August 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary ↗

July 20, 2022

Via Benzinga

The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study ↗

July 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

PTC Stock Has Gained 27% This Week Alone, And It's Still Sprinting ↗

June 23, 2022

Shares of PTC stock continued a seven-day run Thursday on promising test results for its Duchenne muscular dystrophy treatment.

Via Investor's Business Daily

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in PTC Therapeutics, Inc. with Losses to Contact the Firm

June 16, 2022

From The Schall Law Firm

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

May 31, 2022

On Tuesday, 36 companies achieved new lows for the year.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

June 02, 2022

During the Thursday's session, 100 stocks hit new 52-week lows.

Via Benzinga

PTC Therapeutics's Return On Capital Employed Overview ↗

May 12, 2022

According to data from Benzinga Pro, during Q1, PTC Therapeutics's (NASDAQ:PTCT) reported sales totaled $148.74 million. Despite a 11.54% increase in earnings, the company posted a loss of $126.73...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

June 01, 2022

On Wednesday, 73 stocks hit new 52-week lows.

Via Benzinga

Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population ↗

March 16, 2022

Via Benzinga

Earnings Scheduled For May 3, 2022 ↗

May 03, 2022

Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.

Via Benzinga

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

All News about PTC Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today